Allogene Therapeutics, Inc. · NASDAQ:ALLO
Allogene Therapeutics — Q4 2025 Earnings Presentation
26 slides from Allogene Therapeutics's earnings presentation, Mar 12, 2026
Slide 1: Fast-Tracking the Future of Cell Therapy
Fast-Tracking the Future of Cell Therapy: Advancing Biologic-Scale Allogeneic CAR T Toward the Finish Line March 2026 1
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. To the extent that statements contained in this presentation are not descriptions of historical facts regarding Allogene T
Slide 3: Allogeneic CAR T: Scaling Cell Therapy for the Future
Allogeneic CAR T: Scaling Cell Therapy for the Future Foundational Benefits Clinical Utility Patient Accessibility Biologic-like Platform • Durable clinical efficacy • Immediate treatment • Efficient, scalable mfg*: access through off-the- – 30K-60K+ doses/year • Single, one-time dosing shelf availa
Slide 4: Transforming CAR T Therapy from Process to Scalable Product
Transforming CAR T Therapy from Process to Scalable Product AlloCAR T Ex Vivo Product Advantages AlloCAR T In Vivo Clinical Benefits Biologic-like Optimized Multiplex Curative-Intent Economics CAR T Cell Gene and ALLOGENE Persistence Treatment Engineering Paradigm Distribution Combines for Safety th
Slide 5: Three Purpose-Built Programs Designed to Redefine Patient Care
Three Purpose-Built Programs Designed to Redefine Patient Care… Changing the Standard of Care Cema-cel ALPHA3 pivotal RCT in 1L consolidation LBCL w/potential to improve cure rates (CD19) Futility analysis with MRD clearance rate slated for April 2026 Uniquely Engineered for Autoimmune Disease ALLO-
Slide 6: Remove Barriers to Unlock Broader CAR T Market Potential
…and Remove Barriers to Unlock Broader CAR T Market Potential ALPHA3 RESOLUTION TRAVERSE cema-cel (CD19) ALLO-329 (CD19/CD70) ALLO-316 (CD70) ~$5B >$15B >$3.5B Assumes ~15K US/EU patients Based on US prevalence (~500K) Assumes ~9K patients worldwide with treated in LBCL 1L consolidation among rheuma
Slide 7: Cema-Cel: The ALPHA3 Pivotal Study
Cema-Cel: The ALPHA3 Pivotal Study Interim Futility Analysis: April 2026 Giving LBCL Patients a Second Chance at First-Line Success 7
Slide 8: ALPHA3: Disrupting the Course of Disease, Not How Clinicians Practice
ALPHA3: Disrupting the Course of Disease, Not How Clinicians Practice Current Standard of Care Potential for a New Standard of Care* 1L Treatment 1L Treatment ctDNA-based MRD Test + cema-cel Consolidation "Watch and Wait" Until Disease Recurrence Reduce Risk of Recurrence Up to 30% Require 2L Treatm
Slide 9: Changing Paradigm: ctDNA-Guided Early Intervention
Changing Paradigm: ctDNA-Guided Early Intervention MRD Predicts Risk of Relapse1 MRD+ Patients Receive Timely Intervention Patients who are MRD+ at the end of front-line R-CHOP are Median disease burden is >200-fold lower >12X more likely to experience disease relapse2 in patients who are MRD+3 Low
Slide 10: Pivotal ALPHA3 Trial Poised for First Program-Defining Readout
Pivotal ALPHA3 Trial Poised for First Program-Defining Readout 1L LBCL 1:1 Consolidation Randomization Next Key Milestone cema-cel Randomization Interim Interim Primary Following April 2026: Interim MRD Futility EFS EFS Futility Analysis Based Screening Analysis* Analysis Analysis on MRD Clearance R
Slide 11: 25-30% MRD Clearance Rate Difference at Interim Futility Analysis
Early Q2 Interim Futility Analysis Will Focus on the MRD Clearance Difference Polivy in 1L DLBCL (POLARIX): Pola-R-CHP compared to R-CHP reduced the PFS risk by 27%, Sets a new benchmark as the first new approval improving 2-year PFS rate by 6.5% in 1L DLBCL in over a decade Yescarta in 2L DLBCL (ZU
Slide 12: Supercharging Next Generation AlloCAR T Products
Supercharging Next Generation AlloCAR T Products ALLO-329 Initial Proof-of-Concept in Autoimmune Indications: June 2026 ALLO-316 Solid Tumor Dagger® Technology with Built-in Lymphodepletion 12
Slide 13: Dagger Technology: A Transformative Solution to Allo-Rejection
Dagger® Technology: A Transformative Solution to Allo-Rejection The Insights Driving a New Approach to Mitigate Allo-Rejection • Chemotherapy-based lymphodepletion is non-specific, toxic, and ineffective in advanced cancer • Host allo-reactive T cells drive allogeneic CAR T rejection • CD70⁺ activat
Slide 14: Dagger: Clinically Validated, Best-in-Class Allogeneic Platform
Dagger®: Clinically Validated, Best-in-Class Allogeneic Platform Product / Cmax AUC0-28 Clinical Validation of Dagger® Candidate Cell Dose copies/µg day*copies/µg Technology • Translational data from ALLO-316 ALLO-316 80 M 64,647 620,910 demonstrated robust CAR T expansion that matches or exceeds au
Slide 15: ALLO-329: Designed to Control Autoimmune Disease & Minimize Lymphodepletion
ALLO-329: Purposefully Designed to Control Autoimmune Disease & Minimize Lymphodepletion Targets Dual Pathogenic Immune Cell Pathways Dual CD19/CD70 CAR to enable both disease control and immune conditioning • ALLO-329 Eliminates: • Dysfunctional B cells (CD19 CAR) • Activated T cells (CD70 CAR) • E
Slide 16: RESOLUTION: A Platform-Defining PoC for an AlloCAR T in Autoimmune Disease
RESOLUTION: A Platform-Defining PoC for an AlloCAR T in Autoimmune Disease RESOLUTION Protocol Schema of Parallel Dose Escalation With or Without Lymphodepletion DL1 DL2 DL3 Next Key Milestone: PoC with Cy only with Cy only with Cy only June 2026: Biomarker Data and Early Clinical Outcomes (both Cy
Slide 17: ALLO-316: Path to Addressing Unmet Need in Solid Tumors
ALLO-316: Path to Addressing Unmet Need in Solid Tumors Encouraging Activity In Solid Tumor Global Market Opportunity High Unmet Need in r/r RCC • Standard outcomes in r/r RCC are poor: ~20% ORR and <6mo mPFS2a, 2b 31% ORR in r/r RCC with high CD70+ expression • Median DOR not yet reached with longe
Slide 18: ALLO-316 Demonstrates a CAR T Can Deliver Durable Benefit in Solid Tumors
ALLO-316 Demonstrates a CAR T Can Deliver Durable Benefit in Solid Tumors Promising Durable Responses in Refractory Patients Who Had Exhausted All Approved Therapies Prior Therapies Day 28 Month 2 Month 4 Month 6 Month 8 Month 10 Month 12 HIF2α CTLA-4 PD-(L)1/TKI TPS ≥50% TPS <50% PR SD PD Death due
Slide 19: Allogene: Fast-Tracking the Future of Cell Therapy
Allogene: Fast-Tracking the Future of Cell Therapy Led by Cell Therapy Veterans Applying Proven Experience to Deliver the First Scalable, Real-World Allogeneic CAR T Products Built for Biologic-Like Scale Poised to Unlock Multi-Billion Dollar Significant Near-Term Data Events Market Opportunity • Ce
Slide 20: Fast-Tracking the Future of Cell Therapy
Fast-Tracking the Future of Cell Therapy: Advancing Biologic-Scale Allogeneic CAR T Toward the Finish Line Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to
Slide 21: Pipeline Designed to Maximize Greatest Opportunity
Pipeline Designed to Maximize Greatest Opportunity 1 Phase 2 designed to be registrational 21
Slide 22: ctDNA-based MRD Test
Opportunity to Leapfrog Competition with an Alternative to “Watch and Wait” MRD- Remission Standard 1L End of Therapy Evaluation ~60% ctDNA-based MRD Test Cured Future State Responding 1L Therapy LBCL Complete Previously ”Watch and Wait” Response or Diagnosis (e.g., Rituxan- Partial Response Chemo 6
Slide 23: The Right Product: Foundational Ph1 Cema-cel Data Paves the Way for ALPHA3
The Right Product: Foundational Ph1 Cema-cel Data Paves the Way for ALPHA3 Median Time From Enrollment to Treatment = 2 days Patients Who Received KYMRIAH®1 YESCARTA®2 BREYANZI®3 3L Relapsed/Refractory LBCL All Patients (n=33) Selected Ph2 Dose* (n=12) Phase 2 Pivotal Phase 2 Pivotal Phase 2 Pivotal
Slide 24: ALPHA3 Addressable Population Creates a ~$5B Opportunity
ALPHA3 Addressable Population Creates a ~$5B Opportunity 1L Consolidation Potential Market Opportunity Sizing1 US EU5 1L Drug-Treated Patients ~34,000 ~31,000 % CR/PR Who Will Later Relapse w/MRD-Positivity ~30%* % MRD Tested ~75% Potentially US+EU5 Addressable >14,700 Patients/Year Market Opportuni
Slide 25: AID Market Opportunity Has Potential to Greatly Exceed CAR T in Heme Malignancies
AID Market Opportunity Has Potential to Greatly Exceed CAR T in Heme Malignancies Estimated US Diagnosed Prevalence for Select Autoimmune Diseases Rheumatology Neurology Nephrology Hematology GI / Metabolic Warm Autoimmune Lupus (SLE) SPMS / PPMS Lupus Nephritis Ulcerative Colitis Hemolytic Anemia 3
Slide 26: TRAVERSE Addressable Population Creates a >$3.5B Opportunity
TRAVERSE Addressable Population Creates a >$3.5B Opportunity 3L+ ccRCC Potential Market Opportunity Sizing US Ex-US 3L+ Drug-Treated Patients1 ~7,500 ~7,600 % Prior-ICI/TKI ~100% % CD70+2 ~80% % CD70 ~75% TPS ≥ 50%2 Potentially Addressable WW ~9,000 Patients/Year Market Opportunity3 >$3.5B Revenue P
Allogene Therapeutics — Q4 2025 Earnings Presentation on 6ix